Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801002 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
A Phase 1 study of Solid Tumor, sponsored by Jabez Bioscience.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06801002 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Jabez Bioscience. The registered enrollment target is 25 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06801002, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Jabez Bioscience.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and hematological malignancies. The study design includes two independent parts: dose escalation in solid tumors and NHL (Part 1), and up to four indication expansions in selected solid tumor types and NHL (Part 2). The dose escalation will enroll patients with solid tumors and NHL following a standard "3+3" design enrolling a minimum of 3 and up to 6 patients per dose level.
Conditions Studied
Interventions
- DRUG JBZ-001
Study Locations (2)
Ohio
- The Ohio State University - Columbus
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2028-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06801002
The ClinicalTrials.gov registry entry for NCT06801002 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (89% lower). The listed sponsor is Jabez Bioscience, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which JBZ-001 is the first listed.
NCT06801002 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Utah.
Frequently Asked Questions
What is clinical trial NCT06801002 about?
NCT06801002 is a clinical study titled "Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies". This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and hematological malignancies. The study design includes two independent parts: dose e...
What is the current status of trial NCT06801002?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2025-03-17. Estimated completion is 2028-02-15.
What conditions does trial NCT06801002 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06801002?
The interventions under investigation include: JBZ-001 (DRUG).
Who is sponsoring clinical trial NCT06801002?
This trial is sponsored by Jabez Bioscience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06801002 being conducted?
This trial has 2 study locations across Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.